Brief: Hemostemix Announces Convertible Debenture Financing
03/05/2019 13:38
May 3 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES CONVERTIBLE DEBENTURE FINANCING
* HEMOSTEMIX INC - PROCEEDS OF DEBENTURE OFFERING WILL BE
USED TO
CONTINUE TO FUND COMPANY'S PHASE II CLINICAL TRIAL FOR CRITICAL
LIMB ISCHEMIA
Source text for Eikon: ID:nGNX3Tk4VD
Further company coverage: HEM.V
((Briefs@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update